No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - RBC Capital Markets has upped both forecasts and its price target for blue chip generics specialist Hikma Pharmaceuticals.
The broker said Hikma had recently provided mid-term guidance that "reflects growing optimism about the Rx and injectables businesses".
It continued: "This adds to the positive outlook for the branded unit, communicated in late 2024. Overall, Hikma anticipates three-year revenue growth of 6% to 8% per annual, and core operating profit growth of 7% to 9% per annum."
RBC has therefore increased its 2027 forecasts for earnings before interest and tax by 9%, and the price target by 3%, to 2,635p.
It concluded: "With 27% upside, we reiterate our 'outperform' recommendation."
As at 1330 BST, shares in Hikma were largely flat at 2,078p.
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.